Argireline vs Pancragen
Side-by-side comparison of key properties, dosing, and research.
Skin & Cosmetic
ArgirelineAnti-Aging & Longevity
Pancragen- Summary
- Argireline is the most widely researched topical 'Botox-alternative' cosmetic peptide, an acetylated hexapeptide that inhibits neuromuscular transmission to relax facial muscles and reduce dynamic wrinkle depth by 17–27% in clinical studies.
- Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
- Half-Life
- N/A — topical application; effect duration linked to formulation contact time
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- Topical
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 5–10% concentration
- 10 mg per day
- Frequency
- Twice daily
- Daily for 10–30 days
- Key Benefits
- Reduces depth of dynamic expression wrinkles 17–27%
- Non-invasive topical Botox alternative
- Smooths forehead, eye area, nasolabial fold lines
- Widely studied — published clinical efficacy data
- Synergistic with SNAP-8 for enhanced effect
- Reduces fine lines around eyes (crow's feet)
- Improves skin smoothness and texture
- Well tolerated across all skin types
- Supports pancreatic beta cell function and insulin secretion
- May improve glucose metabolism in early metabolic dysfunction
- Protective effects on exocrine pancreatic tissue
- Anti-aging effects on pancreatic cells
- Potential support in type 2 diabetes management alongside standard care
- Reduces pancreatic cellular apoptosis from metabolic stress
- Complementary to GLP-1 agonists in metabolic protocols
- Side Effects
- Generally very well tolerated
- At >10%: temporary eyelid/brow ptosis (drooping)
- Rare: mild redness in sensitive skin
- No systemic absorption at cosmetic doses
- Generally well tolerated
- Mild injection site reactions
- No significant hypoglycemic events reported at standard doses as monotherapy
- Stacks With
- —
- —